PriceTargets.com logo

Mersana Therapeutics - MRSN Stock Price Target and Predictions

  • Consensus Rating: Reduce
  • Consensus Price Target: $38.19
  • Forecasted Upside: 39.02%
  • Number of Analysts: 8
  • Breakdown:
  • 1 Sell Ratings
  • 7 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$27.47 As of 12/4/2025 05:00 PM ET
▼ -0.38 (-1.36%)

This chart shows the closing price for MRSN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Mersana Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MRSN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MRSN

Analyst Price Target is $38.19
▲ +39.02% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Mersana Therapeutics in the last 3 months. The average price target is $38.19, with a high forecast of $75.00 and a low forecast of $17.00. The average price target represents a 39.02% upside from the last price of $27.47.

This chart shows the closing price for MRSN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Reduce

The current consensus among 8 investment analysts is to reduce stock in Mersana Therapeutics. This rating changed within the last month from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
6/12/2024
  • 1 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2024
  • 1 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2024
  • 1 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2025
  • 1 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/7/2025
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2025
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
11/4/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 7 hold ratings
  • 1 sell ratings
Ratings as of
12/4/2025

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 7 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/2/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
11/14/2025GuggenheimDowngradeBuy ➝ Hold
11/13/2025William BlairDowngradeStrong-Buy ➝ Market Perform
11/13/2025Lifesci CapitalDowngradeStrong-Buy ➝ Hold
11/13/2025Leerink PartnrsDowngradeStrong-Buy ➝ Hold
11/13/2025WedbushDowngradeStrong-Buy ➝ Hold
11/13/2025Truist FinancialDowngradeBuy ➝ Hold$36.00 ➝ $30.75
11/13/2025BTIG ResearchDowngradeBuy ➝ Hold
10/8/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
9/27/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
8/14/2025Truist FinancialLower TargetBuy ➝ Buy$250.00 ➝ $36.00
8/14/2025GuggenheimLower TargetBuy ➝ Buy$125.00 ➝ $30.00
8/13/2025BTIG ResearchReiterated RatingBuy ➝ Buy$17.00
6/3/2025William BlairReiterated RatingOutperform
5/16/2025Truist FinancialBoost TargetBuy ➝ Buy$225.00 ➝ $250.00
5/16/2025GuggenheimReiterated RatingBuy ➝ Buy$125.00 ➝ $125.00
5/15/2025WedbushReiterated RatingOutperform$75.00
5/6/2025WedbushReiterated RatingOutperform$100.00 ➝ $75.00
3/3/2025WedbushReiterated RatingOutperform$100.00
2/6/2025William BlairInitiated CoverageOutperform
1/10/2025WedbushReiterated RatingOutperform$175.00 ➝ $100.00
11/15/2024CitigroupInitiated CoverageBuy$125.00
8/27/2024CitigroupLower TargetBuy ➝ Buy$150.00 ➝ $125.00
8/14/2024Robert W. BairdLower TargetNeutral ➝ Neutral$100.00 ➝ $75.00
7/29/2024Lifesci CapitalUpgradeStrong-Buy
3/19/2024JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral$125.00
2/29/2024Truist FinancialUpgradeHold ➝ Buy$225.00
2/29/2024Robert W. BairdBoost TargetNeutral ➝ Neutral$25.00 ➝ $125.00
2/29/2024BTIG ResearchUpgradeNeutral ➝ Buy$150.00
2/29/2024GuggenheimUpgradeNeutral ➝ Buy$175.00
2/29/2024WedbushUpgradeNeutral ➝ Outperform$50.00 ➝ $175.00
12/4/2023CitigroupUpgradeNeutral ➝ Buy$25.00 ➝ $125.00
10/31/2023WedbushReiterated RatingNeutral$50.00
8/8/2023WedbushReiterated RatingNeutral$50.00
7/28/2023Robert W. BairdDowngradeOutperform ➝ Neutral
7/27/2023JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight
7/27/2023CitigroupDowngradeBuy ➝ Neutral
7/27/2023BTIG ResearchDowngradeBuy ➝ Neutral
7/27/2023GuggenheimDowngradeBuy ➝ Neutral
7/27/2023Truist FinancialReiterated RatingBuy ➝ Hold
7/27/2023WedbushReiterated RatingOutperform ➝ Neutral$300.00 ➝ $50.00
6/16/2023Robert W. BairdLower Target$500.00 ➝ $175.00
6/16/2023CitigroupLower Target$375.00 ➝ $250.00
6/15/2023JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$275.00 ➝ $125.00
6/15/2023BTIG ResearchLower Target$400.00 ➝ $250.00
6/14/2023GuggenheimInitiated CoverageBuy$350.00
3/16/2023JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$250.00
3/1/2023BTIG ResearchLower Target$650.00 ➝ $400.00
1/20/2023CitigroupInitiated CoverageBuy$300.00
11/21/2022Truist FinancialInitiated CoverageBuy$300.00
8/9/2022WedbushReiterated RatingOutperform
8/9/2022Robert W. BairdBoost TargetOutperform$450.00 ➝ $500.00
8/9/2022Leerink PartnersBoost TargetOutperform$325.00 ➝ $350.00
5/10/2022Robert W. BairdLower Target$575.00 ➝ $450.00
5/9/2022HC WainwrightLower Target$600.00 ➝ $475.00
2/18/2022Leerink PartnersLower TargetOutperform$625.00 ➝ $400.00
11/10/2021Robert W. BairdLower TargetOutperform$750.00 ➝ $575.00
9/12/2021BTIG ResearchReiterated RatingBuy
8/30/2021HC WainwrightInitiated CoverageBuy$700.00
8/12/2021Robert W. BairdReiterated RatingBuy$750.00
6/29/2021BTIG ResearchReiterated RatingBuy$800.00
3/30/2021Credit Suisse GroupInitiated CoverageNeutral$450.00
(Data available from 12/4/2020 forward)

News Sentiment Rating

0.45 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/8/2025
  • 0 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/7/2025
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
7/7/2025
  • 0 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/6/2025
  • 1 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/5/2025
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/5/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/4/2025
  • 5 very positive mentions
  • 24 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/4/2025

Current Sentiment

  • 5 very positive mentions
  • 24 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Mersana Therapeutics logo
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $27.47
Low: $27.31
High: $28.36

50 Day Range

MA: $15.01
Low: $7.57
High: $27.92

52 Week Range

Now: $27.47
Low: $5.21
High: $70.73

Volume

70,525 shs

Average Volume

233,076 shs

Market Capitalization

$137.35 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.45

Frequently Asked Questions

What sell-side analysts currently cover shares of Mersana Therapeutics?

The following Wall Street research analysts have issued stock ratings on Mersana Therapeutics in the last year: BTIG Research, Guggenheim, Leerink Partnrs, Lifesci Capital, Truist Financial Corporation, Wall Street Zen, Wedbush, Weiss Ratings, and William Blair.
View the latest analyst ratings for MRSN.

What is the current price target for Mersana Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Mersana Therapeutics in the last year. Their average twelve-month price target is $38.19, suggesting a possible upside of 39.0%. Wedbush has the highest price target set, predicting MRSN will reach $75.00 in the next twelve months. BTIG Research has the lowest price target set, forecasting a price of $17.00 for Mersana Therapeutics in the next year.
View the latest price targets for MRSN.

What is the current consensus analyst rating for Mersana Therapeutics?

Mersana Therapeutics currently has 1 sell rating and 7 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Reduce."
View the latest ratings for MRSN.

What other companies compete with Mersana Therapeutics?

Other companies that are similar to Mersana Therapeutics include Bright Minds Biosciences, Design Therapeutics, COMPASS Pathways, ADC Therapeutics and Keros Therapeutics. Learn More about companies similar to Mersana Therapeutics.

How do I contact Mersana Therapeutics' investor relations team?

Mersana Therapeutics' physical mailing address is 840 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The company's listed phone number is (617) 498-0020 and its investor relations email address is [email protected]. The official website for Mersana Therapeutics is www.mersana.com. Learn More about contacing Mersana Therapeutics investor relations.